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Purpose: The present study reports on the biochemical validation of the self-reported   smoking 
status of patients with chronic obstructive pulmonary disease (COPD). The objective is to 
establish the proportion of overestimation of self-reported success rates.
Methods: A cross-sectional smoking-status validation study including 60 patients with COPD 
who reported that they had stopped smoking. In the analysis of urine samples, a cut-off point 
of 50 ng/mL of cotinine was used.
Results: At the time of biochemical validation, 55 patients reported that they had quit   smoking 
while five patients resumed smoking. Smoking status was biochemically confirmed for 43 
patients (78%) and 12 patients (22%) were classified as smokers. The sensitivity of the   self-report 
of smoking was 29% and the specificity was 100%.
Conclusion: Many primary care patients with COPD do not provide valid information on 
their smoking status, which hamper adequate therapeutic interventions. Integration of bio-
chemical validation in daily care could overcome this problem, but may harm the doctor–patient 
relationship.
Keywords: chronic obstructive pulmonary disease, smoking cessation, biochemical validation, 
general practice, outcome measurement
Introduction
Smoking cessation interventions provided in general practice have proven to be 
effective.1,2 The role of general practitioners (GPs) in supporting their patients who want 
to quit smoking is documented in international guidelines.3 Addressing the   smoking 
status of patients can be difficult, but GPs are more likely to do so if their patient suffers 
from smoking-related complaints.4 The GPs’ advice and support encourages patients 
to quit smoking. How do physicians learn whether their support was successful? Are 
they able to rely on the patients’ self-reports?
Chronic obstructive pulmonary disease (COPD) is illustrative of a smoking-related 
disease. This slowly progressive disease is characterized by airflow obstruction with 
related symptoms such as cough, sputum production, dyspnea, and wheeze and it is 
mainly caused by smoking.5–7 Among patients with COPD, smoking prevalence varies 
from 38%–52% in seven countries.8 Because smoking accounts for 80%–90% of COPD, 
one may assume that many patients find it difficult to quit smoking. Smoking cessation 
slows down the rate of deterioration of lung function, improves COPD prognosis, and 
may prolong life expectancy for these patients.9–12 Consequently, smoking cessation is 
the most important element of therapy for COPD,5 and it is necessary to measure the 
results of smoking cessation interventions during the therapeutic process.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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The self-report of smoking cessation in community 
  surveys among the general population is reasonably valid.13–16   
For smokers specially at risk (eg, coronary disease, 
COPD, pregnancy), the self-reported smoking status is 
less reliable.13,17–20 Biochemical testing is recommended 
for   specific populations where quitting is very desirable.21 
Cotinine, the major proximate metabolite of nicotine, has 
been widely used as a biomarker of tobacco exposure. The 
relatively long half-life of cotinine (16–20 hours) enables 
detection for a few days after cessation of tobacco use. The 
sensitivity and specificity of cotinine are high, 97% and 
99%–100%, respectively,22,23 and it is therefore the preferred 
substance to measure.
Although the rationale for biochemical validation of 
the smoking status of patients with increased health risks 
is evident, the Lung Health Study found little discrepancy 
between self-reports and cotinine measurement of patients 
with early-staged COPD.24 Nevertheless, the patients 
who had received smoking cessation support misreported 
their smoking status more often than patients who had not 
(6% versus 1%). This may suggest that participation in a 
  smoking cessation program increases the social desirability 
bias. Participation of COPD patients in an intensive smoking 
  cessation program had even higher rates (52%) of misre-
porting after biochemical testing of their smoking status.20 
Smoking cessation interventions, as carried out in general 
practice during routine follow-up, are generally less intensive 
than these programs.20,24 The question is, then, how accurate 
are the self-reports of COPD patients if they have been sub-
jected to a less intensive smoking cessation intervention in 
the patients’ own general practice? As smoking cessation 
support is recommended in routine general practice for 
patients with COPD, it is important for GPs to obtain valid 
information about their patients’ smoking status. This is 
necessary to use smoking cessation programs effectively 
and to adjust the medical therapy to their results. Since the 
literature is inconclusive about the extent of misreporting of 
the smoking status of COPD smokers in general practice, the 
present study examines the validity of self-reported smoking 
status of COPD patients participating in a study testing a 
moderately intensive smoking cessation program in daily 
general practice.
Methods and materials
The present study is a validation study of self-reported 
smoking status assessed by urine cotinine analysis. The data 
were collected from all patients who reported that they had 
not smoked in the past 7 days.
subjects and procedure
A software program using Anatomical Therapeutical Chemi-
cal (ATC) prescription codes and International Classification 
of Primary Care (ICPC) diagnosis codes selected potential 
patients with COPD from general practices. The criteria 
included age of 35 years or more and a diagnosis recorded 
as COPD, or as ICPC code R95/96, or at least three prescrip-
tions of bronchodilators (ATC code R03a/bc), and/or at least 
two prescriptions of inhaled anti-inflammatory medication in 
the last year (ATC code R03). The GPs had to confirm the 
diagnosis of the selected patients. Patients were eligible to 
  participate if they were: 1) currently smoking; 2) suffering 
from COPD according to the GP’s diagnosis; 3) not being 
treated by a chest physician; 4) in command of the Dutch 
language; and 5) not suffering from any serious physical or 
psychological co-morbidity. The participants consented to 
participate in an intervention study in general practice and 
were allocated to one of the three study groups (including 
a control group). The patient-directed intervention tailored 
to general practice patients with COPD was based on 
the minimal intervention strategy.2 GPs applied a stage-
based protocol, providing information, smoking cessation 
counseling, and advised the use of pharmacological cessation 
aids (ie, nicotine replacement therapy or bupropion-SR). 
The patient education tools consisted of a leaflet especially 
developed for COPD smokers and a videotape. The patients 
included in the present study self-reported to have quit 
smoking during the 12-month follow-up. More   information 
about patient inclusion and the smoking   cessation program 
can be found elsewhere.25–27 Figure 1 shows that of the 
667 enrolled patients, 86 patients said at the 12-month 
follow-up that they were not smoking: however, 22 patients 
(26%) did not enter the present study (17 patients refused 
and five patients were too ill), three patients were excluded 
because of their current nicotine replacement therapy, and 
one patient was excluded due to missing data. Hence, our 
sample consisted of 60 patients. The procedures followed 
were approved by the Committee on Human Experimentation, 
Maastricht University, The Netherlands.
Measurement
The participants were briefed at the beginning of the study 
(1 year prior to the assessment of their smoking status) 
about possible self-report crosschecks with biochemical 
validation. They received a baseline questionnaire (Q0) to 
complete at home to provide the baseline characteristics of 
the sample including their motivation to quit smoking,28 
severity of nicotine dependence (Fagerström Test of Nicotine International Journal of General Medicine 2011:4
667 COPD smokers included in an intervention study
Baseline measurement (questionnaire 0)
Application of a smoking cessation program in general practice
(1–3 consultations + telephone counseling)
OR usual care
Follow-up measurement (12 months) (questionnaire 1)
86 Self-reported quitters5 81 Current smokers
26 Patients dropped out
– 22 nonresponders
– 3 using NRT
– 1 lack of data
Validation questionnaire (questionnaire 2)
55 Quitted smokinga
5 Resumed smokinga
Biochemical validation (urine cotinine test)
43 Quitted smokingb 17 Resumed smokingbc
Figure 1 Flow of the biochemical validation study.
Notes: aself-report, bBiochemically verified, cIncluding the 5 self-reported resumed smokers.
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Dependence),29 and COPD symptoms (Medical Research 
Council).30 Twelve months later, they received another 
questionnaire (Q1) regarding their smoking status (7-day 
point prevalence). The patients who reported that they had 
quit smoking were included in the validation study and 
received a letter in which they were asked to visit the general 
practice within a week to produce and hand over a urine 
sample to be sent to the researchers for analysis. If they were 
unable to visit the practice, a research assistant collected the 
sample during a home visit. Furthermore, they were asked 
to complete an additional short questionnaire at the exact 
time of the sample production (Q2), which included their 
current smoking behavior and use of nicotine substitution. 
All questionnaires were self-administered and were used for International Journal of General Medicine 2011:4
Table  2  Association  between  self-reported  quit  rates  and 
biochemically validated quit rates
Biochemical validation Self-report (questionnaire 2)
Not smoking Smoking
not smoking 43 0
smoking 12 5
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research only. The results of the biochemical validation of 
the self-reported smoking status were not communicated to 
the patients’ GPs.
The amount of urinary cotinine was measured by 
radioimmunoassay. Radioimmunoassay involves the use of 
antibodies to cotinine. The double-antibody technique was 
used to separate free-labeled antigen from antibody-bound 
antigen. A reaction mixture containing 0.1 mL 3H-cotinine, 
appropriately diluted antiserum and buffer (0.14 M NaCl, 
0.01 M Tris-HCl, and 0.1% gelatin) was incubated at 37°C. 
For inhibition experiments, 0.1 mL-aliquots containing 
known amounts of standard or dilution of the urine-samples 
were added in place of buffer. Goat anti-rabbit immunoglobulin 
was added and the mixture was incubated at 4°C overnight. 
To control for nonspecific binding, normal rabbit serum 
was used in place of immune serum. The precipitate was 
  collected by centrifugation at 4200 rpm for 45 minutes at 
4°C, the supernatant decanted, and the walls of the tubes 
wiped dry. To count the 3H-cotinine, the precipitate was 
dissolved in 0.1 mL 0.1 N sodium hydroxide before adding 
2.5 mL   scintillation fluid. Eventually the rate of radioactivity 
was counted and the amount of cotinine could be calculated 
from the linear portion of the standard curve. The results 
were reported in nanograms per milliliter.
Analyses
The cut-off point for both smokers and nonsmokers was 
50 ng/mL.21 We used the contingency coefficient (two-
tailed test) to analyze the association of the self-reported 
status and the biochemically confirmed smoking status. 
Moreover, the sensitivity and specificity of the self-report 
were calculated. Differences in cotinine levels were ana-
lyzed by means of the Mann–Whitney U test (two-tailed). 
The data were analyzed with SPSS software (v. 14.0; SPSS 
Inc., Chicago, IL).
Results
Table 1 shows the baseline characteristics (Q0) of the 
60 participants. Seven patients were allocated to the control 
group. The sample included 59% men, and the participants 
had a mean age of almost 60 years. At baseline, 38% indicated 
they wanted to quit smoking within 1 month, 34% wanted 
to quit within 6 months, and 28% were not motivated to 
quit smoking. Thirty percent suffered from chronic sputum 
production and 35% from chronic coughing.
Forty-three patients (72%) of the 60 patients were 
  classified by the urine cotinine test as nonsmokers (median 
cotinine level 13.0 ng/mL, quartile range 6.0–22.0), and 
17 patients (28%) were classified as smokers (median 
  cotinine level 134.0 ng/mL, quartile range 68.0–194.0) 
(z-6.00; P , 0.001).
During the time of the biochemical validation, 12 of 
the 17 patients, who were classified as smokers, reported 
that they did not smoke (11 had taken part in the smoking 
cessation intervention) and five said that they had smoked 
recently (three had attended the intervention). Thus, the self-
reporting of 43 (78%) of the 55 patients who claimed that 
they were not smoking at the time of taking the urine sample 
(Q2) corresponded with the classification by the cotinine 
level and 12 (22%) patients did not correspond (see Table 2) 
(contingency coefficient 0.43; P , 0.001). The self-report 
had 29% sensitivity for detecting actual smoking, and a 
specificity of 100%.
Discussion
We found a misreport rate of 22%. For COPD patients both 
lower24 and higher20 misreport rates have been described. It is 
important to bear in mind that the self-reporting of smoking 
status was combined with providing a urine sample for 
biochemical validation. This combination might result in a 
lower misreport rate, because the patients are aware that their 
self-reports will be checked. If this is true, then the misre-
porting of 22% could be an underestimation. If the patients 
who refused to be tested (n = 22) were still smoking, then the 
misreport rate could be as high as 42%. The real misreporting 
Table 1 characteristics of 60 self-reported quitters
Variable Sample
Men (%) 59
Mean age (sD) 59.9 (11.0)
stages of change (%)
  Preparer 38
  contemplator 34
  Precontemplator 28
Mean number of cigarettes per day (sD) 16.4 (8.2)
Mean FTnD (sD) 4.2 (2.4)
chronic sputum (%) 30
chronic coughing (%) 35
Mean dyspnea, range 0–3 (sD) 1.3 (1.1)
Note: Percentages are rounded.
Abbreviations: FTnD, Fagerström Test of nicotine Dependence; sD, 
standard deviation.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
89
Biochemically verified smoking cessation in COPD patients
figures will probably lie somewhere between these figures. 
The low sensitivity of self-reports (29%), even in a situation 
where the report may be biochemically verified, shows their 
restricted value in clinical smoking cessation programs for 
high-risk populations.
There may be several explanations for the difference 
between self-reported and biochemically determined smoking 
status. First, the time elapsed between the two measurements 
(Q1 and Q2) might be a factor. One of the reasons for the 
great percentage of misreports might be that patients had 
relapsed to smoking after Q1. We tried to overcome this 
problem by reassessing the smoking status (Q2), which 
showed that some of the COPD patients had indeed resumed 
  smoking. Second, the results did not account for the   influence 
of environmental tobacco smoke, which is known to   influence 
cotinine levels.31 However, since our cut-off point was 
50 ng/mL this is not likely. Third, misreporting might be 
triggered by the fact that patients participated in a smoking 
cessation intervention.24 Of the 12 patients who misreported 
their smoking status, 11 participated in the intervention. 
Interestingly, while Monninkhof et al report a misreport 
rate of 52% for COPD patients participating in an intensive 
smoking cessation intervention, they found a misreport rate 
of 13.6% at baseline (ie, for patients not participating in a 
smoking cessation intervention).20 This suggests that although 
biochemical validation of self-reported smoking status of 
COPD patients is recommendable in any situation to obtain 
valid data, participation in an intensive smoking cessation 
program may increase these misreport rates.
Although the number of participating patients might 
limit the external validity of our results, our population is 
a reflection of the self-reported quitters with COPD from a 
large sample of patients treated in general practice. However, 
the small numbers of patients that misreported their smoking 
status hampered in-depth analyses of factors contributing to 
(in)valid self-reports.
Our results show that the self-reporting of quitting by 
COPD smokers is not always trustworthy. A general question 
remains how should medical professionals deal with patients 
who need ongoing medical attention for chronic smoking-
related diseases and who may lie about their smoking 
behavior? In our study we did not communicate the results 
of the biochemical validation to the GPs because they were 
used for research purposes, but some argue that biochemical 
validation should be integrated in the therapeutic process.
Clinical practice teaches that some physicians are 
reluctant to treat patients with COPD who persist in   smoking. 
They argue that treating symptoms that are consciously 
caused by the patient’s persistence in an unhealthy lifestyle 
is a waste of valuable time and effort. In this case, bio-
chemical validation might be a good instrument for assessing 
smoking and for increasing the pressure on the patient to 
quit smoking. Apart from the questions of which measure-
ment is feasible in routine daily general practice and which 
measurement has good sensitivity and specificity (eg, carbon 
monoxide or cotinine measures), this harsh approach might 
damage the relationship with the patient and it questions 
the ethical codes for health professionals. Misreporting 
one’s smoking behavior, lying about it, social desirability 
bias; whatever we call it, it is probably a result of feeling 
ashamed or guilty, and therefore one might ask whether it 
is wise to apply biochemical validation tests as a sort of lie 
detector. Besides the ethical problem, Bize et al found in 
their   systematic review no sufficient evidence that providing 
this kind of biomedical feedback contributes to successful 
smoking cessation.32 Therefore, in spite of the importance 
of getting a reliable view of the patients’ smoking status in 
the context of therapeutic general practice interventions, we 
do not have a clear-cut answer on how best to obtain this 
information in a real-life general practice setting. Ethical 
issues concerning the patient’s own responsibility and the 
effectiveness of biomedical feedback should be weighed 
against the professional need of getting reliable information 
about therapeutic patient outcomes.
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